TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer - PubMed (original) (raw)
TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer
Scott A Tomlins et al. Cancer Res. 2006.
Abstract
Although common in hematologic and mesenchymal malignancies, recurrent gene fusions have not been well characterized in epithelial carcinomas. Recently, using a novel bioinformatic approach, we identified recurrent gene fusions between TMPRSS2 and the ETS family members ERG or ETV1 in the majority of prostate cancers. Here, we interrogated the expression of all ETS family members in prostate cancer profiling studies and identified marked overexpression of ETV4 in 2 of 98 cases. In one such case, we confirmed the overexpression of ETV4 using quantitative PCR, and by rapid amplification of cDNA ends, quantitative PCR, and fluorescence in situ hybridization, we show that the TMPRSS2 (21q22) and ETV4 (17q21) loci are fused in this case. This result defines a third molecular subtype of prostate cancer and supports the hypothesis that dysregulation of ETS family members through fusions with TMRPSS2 may be an initiating event in prostate cancer development.
Similar articles
- Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer.
Helgeson BE, Tomlins SA, Shah N, Laxman B, Cao Q, Prensner JR, Cao X, Singla N, Montie JE, Varambally S, Mehra R, Chinnaiyan AM. Helgeson BE, et al. Cancer Res. 2008 Jan 1;68(1):73-80. doi: 10.1158/0008-5472.CAN-07-5352. Cancer Res. 2008. PMID: 18172298 - Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer.
Winnes M, Lissbrant E, Damber JE, Stenman G. Winnes M, et al. Oncol Rep. 2007 May;17(5):1033-6. Oncol Rep. 2007. PMID: 17390040 - Two unique novel prostate-specific and androgen-regulated fusion partners of ETV4 in prostate cancer.
Hermans KG, Bressers AA, van der Korput HA, Dits NF, Jenster G, Trapman J. Hermans KG, et al. Cancer Res. 2008 May 1;68(9):3094-8. doi: 10.1158/0008-5472.CAN-08-0198. Cancer Res. 2008. PMID: 18451133 - Clinical applications of novel ERG immunohistochemistry in prostate cancer diagnosis and management.
Shah RB. Shah RB. Adv Anat Pathol. 2013 Mar;20(2):117-24. doi: 10.1097/PAP.0b013e3182862ac5. Adv Anat Pathol. 2013. PMID: 23399797 Review.
Cited by
- Advances in sequencing and omics studies in prostate cancer: unveiling molecular pathogenesis and clinical applications.
Lu B, Liu Y, Yao Y, Yang T, Zhang H, Yang X, Huang R, Zhou W, Pan X, Cui X. Lu B, et al. Front Oncol. 2024 May 10;14:1355551. doi: 10.3389/fonc.2024.1355551. eCollection 2024. Front Oncol. 2024. PMID: 38800374 Free PMC article. - Systematic review and integrated analysis of prognostic gene signatures for prostate cancer patients.
An Y, Lu W, Li S, Lu X, Zhang Y, Han D, Su D, Jia J, Yuan J, Zhao B, Tu M, Li X, Wang X, Fang N, Ji S. An Y, et al. Discov Oncol. 2023 Dec 19;14(1):234. doi: 10.1007/s12672-023-00847-4. Discov Oncol. 2023. PMID: 38112859 Free PMC article. - Biomarkers for Prostate Cancer: From Diagnosis to Treatment.
Chen JY, Wang PY, Liu MZ, Lyu F, Ma MW, Ren XY, Gao XS. Chen JY, et al. Diagnostics (Basel). 2023 Oct 31;13(21):3350. doi: 10.3390/diagnostics13213350. Diagnostics (Basel). 2023. PMID: 37958246 Free PMC article. Review. - RSPO2 as Wnt signaling enabler: Important roles in cancer development and therapeutic opportunities.
Srivastava A, Rikhari D, Srivastava S. Srivastava A, et al. Genes Dis. 2023 Apr 19;11(2):788-806. doi: 10.1016/j.gendis.2023.01.013. eCollection 2024 Mar. Genes Dis. 2023. PMID: 37692504 Free PMC article. Review. - Unravelling the Role of P300 and TMPRSS2 in Prostate Cancer: A Literature Review.
Gioukaki C, Georgiou A, Gkaralea LE, Kroupis C, Lazaris AC, Alamanis C, Thomopoulou GE. Gioukaki C, et al. Int J Mol Sci. 2023 Jul 11;24(14):11299. doi: 10.3390/ijms241411299. Int J Mol Sci. 2023. PMID: 37511059 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
- 5P30 CA 46592/CA/NCI NIH HHS/United States
- P50 CA 69568/CA/NCI NIH HHS/United States
- R01 AG 21404/AG/NIA NIH HHS/United States
- R01 CA 97063/CA/NCI NIH HHS/United States
- U01 CA 111275-01/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical